Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Name: Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Published: 2018
License: Public Domain

Novartis Pharmaceuticals · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

breast-cancer

breast cancer, hormone receptor-positive, estrogen and/or progesterone receptor-positive, her2-negative, intermediate risk early breast cancer, adjuvant, ribociclib, lee011, cdk4/6 inhibitor, endocrine therapy, phase iii, breast carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 839792
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.